author-photo

Candis Morrison

National Institutes of Health

15

Papers

272

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.

2021 Oncologist
Show All
- Source
- Cite
- Save
Citations (4)
Diagnostic performance of skeletal survey versus 18F-FDG-PET/CT for detecting lytic lesions in smoldering multiple myeloma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

2020 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models.

2020 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Using Current Clinical Markers to Define High Risk Smoldering Multiple Myeloma: Agree to Disagree

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A Phase 2 Study of Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide Maintenance (KRd-r) in Newly Diagnosed Multiple Myeloma (NDMM): Sustained Long Term Deep Remissions and Prolonged Progression-Free Duration Regardless of Age or Cytogenetic Risk after 5 Years of Follow up

2018 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma

2017 Blood Advances
Show All
- Source
- Cite
- Save
Citations (30)
Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study

2016 Blood
Show All
- Source
- Cite
- Save
Citations (5)